InMed Pharmaceuticals Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q3 2019 to Q1 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
InMed Pharmaceuticals Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q3 2019 to Q1 2023.
- InMed Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending March 31, 2023 was -$2M, a 42.5% increase year-over-year.
- InMed Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending March 31, 2023 was -$15.5M, a 10.7% decline year-over-year.
- InMed Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$18.6M, a 90.3% decline from 2021.
- InMed Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$9.77M, a 4.42% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)